Insider Selling: Twist Bioscience (NASDAQ:TWST) Insider Sells 402 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 402 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $69.84, for a total value of $28,075.68. Following the completion of the transaction, the insider owned 119,692 shares in the company, valued at $8,359,289.28. The trade was a 0.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Performance

Shares of NASDAQ TWST traded down $2.29 during midday trading on Wednesday, reaching $67.77. The company’s stock had a trading volume of 1,145,142 shares, compared to its average volume of 1,390,736. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $80.50. The firm has a 50 day moving average price of $58.12 and a 200-day moving average price of $46.63. The stock has a market capitalization of $4.22 billion, a P/E ratio of -50.95 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter in the previous year, the firm earned ($0.66) EPS. Twist Bioscience’s quarterly revenue was up 19.3% on a year-over-year basis. As a group, equities analysts predict that Twist Bioscience Corporation will post -1.99 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. Western Wealth Management LLC bought a new stake in Twist Bioscience during the 1st quarter valued at $31,000. Strs Ohio bought a new stake in Twist Bioscience during the 1st quarter valued at $33,000. PNC Financial Services Group Inc. raised its holdings in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after acquiring an additional 453 shares during the period. Quarry LP bought a new stake in Twist Bioscience during the 3rd quarter valued at $28,000. Finally, Strategic Advocates LLC raised its holdings in Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on TWST shares. Robert W. Baird boosted their target price on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a report on Friday, May 22nd. Guggenheim lifted their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Barclays lifted their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, May 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $58.00.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.